Skip to main content
. 2024 Apr 24;10(2):e12465. [Article in Dutch] doi: 10.1002/trc2.12465

FIGURE 3.

FIGURE 3

Mechanisms of action of agents in Phase 3 Alzheimer clinical trials as classified using 4 categories of therapeutic purpose (left) or the Common Alzheimer's Disease Research Ontology (CADRO) approach (right)(figure © J Cummings; M de la Flor, PhD, Illustrator).